Prochlorperazine — $0 with Membership

Other medications in Digestive Health

• Prucalopride
• Psyllium
• Rabeprazole
• Senna
• Teduglutide
• Tegaserod
• Ustekinumab
• Vedolizumab

About Prochlorperazine

Prochlorperazine is a versatile medication often prescribed to combat severe nausea, vomiting, and even certain anxiety disorders. At TheDrugClub, we understand the importance of affordable access to your prescriptions. Discover how our membership can help you save on prochlorperazine and other vital medications, making your health journey more manageable.

What is Prochlorperazine and What Does it Treat? Prochlorperazine is a prescription medication primarily known for its powerful anti-emetic (anti-nausea and anti-vomiting) properties. It's frequently prescribed to alleviate severe nausea and vomiting associated with various conditions, including chemotherapy, surgery, and gastroenteritis. Beyond its role in digestive comfort, prochlorperazine is also used to manage certain types of severe anxiety and can sometimes be prescribed off-label for migraine headaches. It's available in several forms, including tablets, suppositories, and injectables, allowing for flexible administration depending on the patient's needs and the severity of their symptoms.

How Does Prochlorperazine Work? Prochlorperazine belongs to a class of drugs called phenothiazine antipsychotics, though it's used at lower doses for its anti-nausea effects. Its primary mechanism of action involves blocking dopamine D2 receptors in the brain, particularly in an area known as the chemoreceptor trigger zone (CTZ). The CTZ is responsible for detecting toxins in the blood and triggering the vomiting reflex. By blocking dopamine in this region, prochlorperazine effectively suppresses the signals that lead to nausea and vomiting. Additionally, its effects on other dopamine receptors and neurotransmitters contribute to its anxiolytic (anti-anxiety) properties, helping to calm the central

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Prochlorperazine is approved for (FDA label)

Prochlorperazine Suppositories, USP 25 mg are indicated in the control of severe nausea and vomiting in adults.

Source: Read the full FDA label on DailyMed. Label effective date: December 17, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Prochlorperazine (FDA label)

WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Prochlorperazine Suppositories, USP is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: 9595346e-76e5-e155-341b-ffaaafb885ab. SPL document ID: 462a6c34-db6d-8d31-e063-6294a90ae196. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Prochlorperazine (FDA label)

Drowsiness, dizziness, amenorrhea, blurred vision, skin reactions and hypotension may occur. Cholestatic jaundice has occurred. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment. There have been a few observations of fatty changes in the livers of patients who have died while receiving the drug. No causal relationship has been established. Leukopenia and agranulocytosis have occurred. Warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate leukocyte depression, stop treatment and start antibiotic and other suitable therapy. Neuromuscular (Extrapyramidal) Reactions These symptoms are seen in a significant number of hospitalized mental patients.

Source: FDA prescribing information (DailyMed). Set ID: 9595346e-76e5-e155-341b-ffaaafb885ab. SPL document ID: 462a6c34-db6d-8d31-e063-6294a90ae196. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Prochlorperazine (FDA label)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). Do not use in pediatric surgery. Do not use in children under 2 years of age or under 20 lbs. Do not use in children for conditions for which dosage has not been established.

Source: FDA prescribing information (DailyMed). Set ID: 9595346e-76e5-e155-341b-ffaaafb885ab. SPL document ID: 462a6c34-db6d-8d31-e063-6294a90ae196. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.